---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-24-006247"
form_type: "8-K"
ticker: "CMPX"
cik: "0001738021"
company_name: "Compass Therapeutics, Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T02:03:55.039313+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Compass Therapeutics Q3 2024 net loss $10.5M ($0.08/share); cash $135M

## Summary
- Net loss $10.5M vs $10.0M in Q3 2023; diluted EPS $0.08 unchanged.
- Cash and marketable securities $135M as of Sep 30, 2024; runway into Q1 2027.
- Phase 2/3 CTX-009 BTC trial fully enrolled; top-line data expected end of Q1 2025.
- CTX-009 Phase 2 in DLL4-positive CRC second-line planned for mid-2025.
- CTX-471 Phase 2 trial in NCAM-expressing tumors planned for mid-2025 based on biomarker data.

## SEC filing metadata
- accession: 0001171843-24-006247
- form_type: 8-K
- ticker: CMPX
- cik: 0001738021
- company_name: Compass Therapeutics, Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1738021/000117184324006247/0001171843-24-006247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1738021/000117184324006247/f8k_111224.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-24-006247
- JSON: https://secwatch.observer/filing/0001171843-24-006247.json
- Plain text: https://secwatch.observer/filing/0001171843-24-006247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.